Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ATRC 
AtriCure Inc (ATRC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ATRC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $50
1 Year Target Price $50
| 5 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.84B USD | Price to earnings Ratio - | 1Y Target Price 50 |
Price to earnings Ratio - | 1Y Target Price 50 | ||
Volume (30-day avg) 9 | Beta 1.62 | 52 Weeks Range 25.50 - 43.11 | Updated Date 08/29/2025 |
52 Weeks Range 25.50 - 43.11 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.77 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -7.27% | Operating Margin (TTM) -4.55% |
Management Effectiveness
Return on Assets (TTM) -3.53% | Return on Equity (TTM) -7.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1809341666 | Price to Sales(TTM) 3.68 |
Enterprise Value 1809341666 | Price to Sales(TTM) 3.68 | ||
Enterprise Value to Revenue 3.62 | Enterprise Value to EBITDA -135.97 | Shares Outstanding 49701400 | Shares Floating 47931051 |
Shares Outstanding 49701400 | Shares Floating 47931051 | ||
Percent Insiders 3.23 | Percent Institutions 100.56 |
Upturn AI SWOT
AtriCure Inc
Company Overview
History and Background
AtriCure, Inc. was founded in 2000 and is headquartered in Mason, Ohio. It is a medical device company focusing on developing, manufacturing, and selling innovative solutions for the treatment of atrial fibrillation (Afib) and related conditions.
Core Business Areas
- Atrial Fibrillation (Afib) Therapy: Develops and markets surgical ablation systems and related devices for treating Afib, including radiofrequency (RF) and cryoablation technologies.
- Pain Management: Offers cryo nerve block products used for pain management following surgery.
Leadership and Structure
Michael Carrel serves as the President and CEO. The company has a typical organizational structure with departments for R&D, Manufacturing, Sales & Marketing, Finance, and Operations.
Top Products and Market Share
Key Offerings
- Isolator Synergy Ablation System: A bipolar radiofrequency ablation system designed for epicardial ablation of atrial tissue to isolate the pulmonary veins, a key element in treating Afib. Market share is estimated around 25-30% in the surgical ablation market. Competitors include Medtronic, Abbott, and Biosense Webster (Johnson & Johnson).
- CryoICE Cryoablation System: Uses cryoablation (freezing) to create lesions for atrial ablation. Market share is smaller than the RF system, estimated around 10-15% in the surgical ablation market. Competitors include Medtronic, Abbott, and Boston Scientific in cryoablation segment.
- AtriClip Left Atrial Appendage Exclusion System: A clip-like device used to occlude the left atrial appendage, reducing the risk of stroke in patients with Afib. Market share is estimated around 40-45% in the LAA management market. Competitors include Boston Scientific (WATCHMAN FLX), Abbott (AMPLATZER Amulet).
Market Dynamics
Industry Overview
The atrial fibrillation market is growing due to the aging population, increasing prevalence of Afib, and technological advancements in ablation techniques. It includes catheter and surgical ablation procedures.
Positioning
AtriCure is a leader in surgical ablation for Afib, particularly with its RF ablation technology and LAA management solutions. Its competitive advantage lies in its focus on surgical approaches and specialized product portfolio.
Total Addressable Market (TAM)
The global atrial fibrillation market is expected to reach USD 35.2 billion by 2030. AtriCure is targeting the surgical ablation and LAA management segments, which represent a significant portion of this TAM. AtriCure is positioned as a key player in the surgical treatment portion of the overall Afib market, holding a meaningful share within surgical ablation and left atrial appendage management.
Upturn SWOT Analysis
Strengths
- Strong market position in surgical ablation
- Innovative product portfolio
- Established relationships with cardiac surgeons
- Focus on a specific therapeutic area
- Global presence
Weaknesses
- Reliance on surgical procedures, which can be more invasive
- Smaller size compared to larger competitors
- Exposure to reimbursement pressures
- Dependence on specialized surgical skills
Opportunities
- Expanding the use of LAA exclusion devices
- Developing new ablation technologies
- Penetrating emerging markets
- Partnering with other medical device companies
- Increased awareness of Afib and its treatments
Threats
- Competition from larger medical device companies
- Technological advancements in catheter-based ablation
- Regulatory changes
- Economic downturns
- Reimbursement cuts
Competitors and Market Share
Key Competitors
- MDT
- ABT
- JNJ
Competitive Landscape
AtriCure faces stiff competition from larger, more diversified medical device companies. It competes effectively in the surgical ablation and LAA management segments due to its specialized products and focus on cardiac surgeons.
Major Acquisitions
SentreHEART, Inc.
- Year: 2021
- Acquisition Price (USD millions): 300
- Strategic Rationale: Acquisition added a percutaneous LAA closure system to AtriCure's portfolio.
Growth Trajectory and Initiatives
Historical Growth: AtriCure has experienced revenue growth driven by increased adoption of its ablation and LAA management products.
Future Projections: Analysts project continued revenue growth driven by increasing Afib prevalence and adoption of minimally invasive surgical techniques. Profitability is expected to improve over time.
Recent Initiatives: Focus on expanding its product portfolio, increasing its sales force, and penetrating new markets.
Summary
AtriCure is a key player in the surgical treatment of atrial fibrillation, particularly in ablation and LAA management. The company is innovative, but it is not yet profitable and faces competition from larger firms. Revenue continues to grow, and strategic acquisitions provide new growth oppourtunities. They need to improve profitability and continue to watch out for competitors' technological advances and reimbursement pressures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10K, 10Q)
- Analyst Reports
- Industry Publications
- Company Website
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and based on available data. Investing in stocks carries risk, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AtriCure Inc
Exchange NASDAQ | Headquaters Mason, OH, United States | ||
IPO Launch date 2005-08-05 | CEO, President & Director Mr. Michael H. Carrel | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1300 | Website https://www.atricure.com |
Full time employees 1300 | Website https://www.atricure.com | ||
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.